"N Engl J Med"[journal] 检索结果

1. The Health Equity, Medical, and Scientific Costs of Dismantling DEI.

作者: Crystal W Cené.
来源: N Engl J Med. 2025年

2. Cutaneous Extramedullary Plasmacytoma after Bone Fracture.

作者: Madeline Conlon.;Katie McBee.
来源: N Engl J Med. 2025年

3. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.

作者: Julio Rosenstock.;Stanley Hsia.;Luis Nevarez Ruiz.;Sarah Eyde.;David Cox.;Wen-Shuo Wu.;Rong Liu.;Jianghao Li.;Laura Fernández Landó.;Max Denning.;Lisa Ludwig.;Yanyun Chen.; .
来源: N Engl J Med. 2025年

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed.

4. My Brother's Keeper.

作者: Joshua A Budhu.
来源: N Engl J Med. 2025年

5. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

作者: W Timothy Garvey.;Matthias Blüher.;Cynthia Karenina Osorto Contreras.;Melanie J Davies.;Eva Winning Lehmann.;Kirsi H Pietiläinen.;Domenica Rubino.;Paolo Sbraccia.;Thomas Wadden.;Niels Zeuthen.;John P H Wilding.; .
来源: N Engl J Med. 2025年

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown.

6. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

作者: Melanie J Davies.;Harpreet S Bajaj.;Christa Broholm.;Astrid Eliasen.;W Timothy Garvey.;Carel W le Roux.;Ildiko Lingvay.;Christian Bøge Lyndgaard.;Julio Rosenstock.;Sue D Pedersen.; .
来源: N Engl J Med. 2025年

Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring.

7. Regulatory Policy to Address Ultraprocessed Foods.

作者: Dariush Mozaffarian.
来源: N Engl J Med. 2025年

8. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.

作者: Trevor W Reichman.;James F Markmann.;Jon Odorico.;Piotr Witkowski.;John J Fung.;Martin Wijkstrom.;Fouad Kandeel.;Eelco J P de Koning.;Anne L Peters.;Chantal Mathieu.;Leslie S Kean.;Bote G Bruinsma.;Chenkun Wang.;Molly Mascia.;Bastiano Sanna.;Gautham Marigowda.;Felicia Pagliuca.;Doug Melton.;Camillo Ricordi.;Michael R Rickels.; .
来源: N Engl J Med. 2025年

Zimislecel is an allogeneic stem cell-derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed.

9. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.

作者: Ravindra Uppaluri.;Robert I Haddad.;Yungan Tao.;Christophe Le Tourneau.;Nancy Y Lee.;William Westra.;Rebecca Chernock.;Makoto Tahara.;Kevin J Harrington.;Arkadiy L Klochikhin.;Irene Braña.;Gustavo Vasconcelos Alves.;Brett G M Hughes.;Marc Oliva.;Iane Pinto Figueiredo Lima.;Tsutomu Ueda.;Tomasz Rutkowski.;Ursula Schroeder.;Paul-Stefan Mauz.;Thorsten Fuereder.;Simon Laban.;Nobuhiko Oridate.;Aron Popovtzer.;Nicolas Mach.;Yevhen Korobko.;Diogo Alpuim Costa.;Anupama Hooda-Nehra.;Cristina P Rodriguez.;R Bryan Bell.;Cole Manschot.;Kimberly Benjamin.;Burak Gumuscu.;Douglas Adkins.; .
来源: N Engl J Med. 2025年

The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear.

10. Revised Recommendations for Covid-19 Vaccines - U.S. Vaccination Policy under Threat.

作者: Jason L Schwartz.
来源: N Engl J Med. 2025年

11. Biologic Drugs and Medicare Price Negotiation.

作者: Thomas J Hwang.;Nancy L Keating.;Stacie B Dusetzina.
来源: N Engl J Med. 2025年

12. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis. Reply.

作者: Anneke C Hesseling.;H Simon Schaaf.;Susan E Purchase.
来源: N Engl J Med. 2025年392卷23期2391-2392页

13. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis. Reply.

作者: Greg J Fox.;Nguyen Viet Nhung.;Guy B Marks.
来源: N Engl J Med. 2025年392卷23期2390-2391页

14. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis.

作者: Mao-Shui Wang.
来源: N Engl J Med. 2025年392卷23期2390页

15. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis.

作者: Ronald Lubelchek.
来源: N Engl J Med. 2025年392卷23期2389-2390页

16. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis.

作者: Saul Malozowski.
来源: N Engl J Med. 2025年392卷23期2389页

17. Oral Infigratinib Therapy in Children with Achondroplasia. Reply.

作者: Ravi Savarirayan.;Daniela Rogoff.
来源: N Engl J Med. 2025年392卷23期2388-2389页

18. Oral Infigratinib Therapy in Children with Achondroplasia.

作者: Gustavo Rico-Llanos.;Aleksandra A Czyrek.;Pavel Krejci.
来源: N Engl J Med. 2025年392卷23期2388页

19. Oral Infigratinib Therapy in Children with Achondroplasia.

作者: Stefan Bittmann.
来源: N Engl J Med. 2025年392卷23期2387-2388页

20. Three Cases of Vertical Transmission of Clade Ib Mpox Virus.

作者: Emmanuel Hasivirwe Vakaniaki.;Nono-Raymond Swar Kuispond.;Yuichiro Hirata.;Eugene Bangwen.;Isabel Brosius.;Eddy Kinganda-Lusamaki.;Seiya Ozono.;Harutaka Katano.;Laurent Gabanga Ndunge.;Noella Mulopo-Mukanya.;Jean-Claude Tshomba.;Elise De Vos.;Christophe Van Dijck.;Papy Munganga.;Guy Mukari.;Yves Mujula.;Divin Mazambi Mambo.;Steeven Bilembo Kitwanda.;Nadine Maliyamungu-Bubala.;Léandre Mutimbwa-Mambo.;Ian Crozier.;Lori E Dodd.;Olivier Tshiani-Mbaya.;Bienvenu Massamba Lebwaze.;Espoir Bwenge Malembaka.;Isaac Barhishindi.;Susanne Krasemann.;Robert Colebunders.;Patrick D M C Katoto.;Sheila Makiala-Mandanda.;Jason Kindrachuk.;Anne W Rimoin.;Jean-Jacques Muyembe-Tamfum.;Daniel Mukadi-Bamuleka.;Tony Wawina-Bokalanga.;Sabin Sabiti Nundu.;Tadaki Suzuki.;Raphaël Bulakali Chirimwami.;Laurens Liesenborghs.;Placide Mbala-Kingebeni.
来源: N Engl J Med. 2025年392卷23期2385-2387页

结果排序

文献格式

出版时间

出版类型

出版语言